Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIC2 (Hypermethylated in cancer 2) is a penta-dactyl zinc finger DNA binding protein containing a BTB/POZ domain that acts as a critical regulator of the fetal-to-adult hemoglobin switch. It functions by directly binding to and decommissioning the +55 erythroid enhancer of the BCL11A gene, thereby repressing BCL11A transcription. Since BCL11A is a major repressor of fetal hemoglobin (HbF), the downregulation of BCL11A by HIC2 leads to the induction of fetal γ-globin (HBG1/2) production. Research conducted at the Children's Hospital of Philadelphia and the University of Pennsylvania has demonstrated that HIC2 overexpression can significantly increase HbF levels and reduce cell sickling in sickle cell disease (SCD) patient-derived erythroid cells, suggesting its potential as a therapeutic target for SCD and β-thalassemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HIC2.